DECEMBER - 20225TECH OUTLOOKCXO INSIGHTSC O NT E NT SAccelerating Drug Development of Novel Targeted Therapies through Histology-Agnostic Oncology Clinical TrialsHua Gong, SVP, Global Head of Translational Medicine and Clinical Biomarker, Zai Lab273D Bioprinting: Accelerating Drug DiscoveryItedale Namro Redwan, CSO, CELLINK18Leveraging AI/ML to Transform Pharmaceutical IndustryAlexander Bernikov, Medical Director, Clinical Development (Uro)-Oncology, Jiangsu Hengrui Pharmaceuticals20Of Mice, Men, and Monkeys: how Humanized Mouse Models are Changing the Antibody Preclinical Development LandscapeAdriano Flora, Director of Business Development, The Jackson Laboratory28Medical Affairs Takes Centre StageDr Sarah Tregenza, PhD BSc (Hons), APAC Oncology Medical Affairs Director, Pierre Fabre Group22Immunotherapy: Shaping a New Era of Patient Centric CareDanie du Plessis, Executive VP Medical Affairs, Kyowa Kirin [TYO: 4151]21The Ever-Evolving Challenges in Drug Development and ManufacturingKimberly Paris, SVP & Chief Compliance Officer, Quotient Sciences24
< Page 4 | Page 6 >